Autopsy report · NCT01982071

A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia

“Due to administrative reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 1 year 11 months before it stopped.
• 59 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Astellas Pharma China, Inc.

Sponsor type

Industry

Conditions

Candidemia; Candidiasis

Interventions

Micafungin

Participants

59

Sites

15

Countries

China

Trials that died the same way

• Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers
  “Due to administrative reason” (96% match in meaning)
• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  “Due to business reasons” (85% match in meaning)
• Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.
  “Administrative reasons.” (80% match in meaning)
• Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
  “Due to financial reasons.” (79% match in meaning)
• The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients
  “due to organizational reason” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.